University of California San Francisco
Give to UCSF
Researchers have figured out how to assemble genetic profiles of individual lung cancer cells obtained from patients at different times during the course of their treatment.
UCSF Medical Center has been recognized as one of the nation’s finest hospitals in the U.S. News & World Report 2020-2021 Best Hospitals survey, ranking among the top 10 hospitals nationwide for the 22nd year.
When your child has a serious medical condition, social distancing is all too familiar. Five families have some advice for the rest of us.
None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black Americans from benefiting from a new generation of precision prostate cancer therapies, researchers say, as long as the therapies are applied equitably.
A new model of the causes of breast cancer, created by a team led by researchers at UCSF, Genentech and Stanford University, is designed to capture the complex interrelationships between dozens of primary and secondary breast cancer causes and stimulate further research.
Colleagues are mourning the passing of Zena Werb, PhD, a giant in the field of cancer biology whose four decades of research at UCSF informed the rise of immunotherapy and other modern approaches to cancer treatment.
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.
The finding could offer additional insights into other immune conditions, including a type of childhood leukemia and the severe inflammation response in some children with COVID-19.
The annual U.S. News rankings serve as a guide of hospitals nationwide that excel in treating children with the most challenging diagnoses.
Depending on a cancer’s tissue of origin, tumors cause widespread and variable disruption of the immune system throughout the body, not just at the primary tumor site.
Cancer specialists from UCSF will present new research findings at the annual scientific program of the American Society of Clinical Oncology, the world’s largest clinical cancer research meeting.
Two UCSF faculty will lead the new institutes.
Cancer and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, might not seem to have much in common, but some researchers now are pinning hopes on the same immune system cell –
UCSF researchers now have reported a new method to design and test cell therapies, one they expect will speed the development of new life-saving treatments not only for cancer, but for other diseases, too.
The Cancer Center, which opened Feb. 3, 2020, is located in the jointly operated Berkeley Outpatient Center.
Survival may more than double for adults with glioblastoma, if neurosurgeons remove the surrounding tissue as aggressively as they remove the cancerous core of the tumor.
UCSF postdoctoral researcher for the first time succeeded in keeping a diverse array of glioblastomas alive in the lab using brain organoids
Basic scientist Zena Werb, who has studied cancer cells in UCSF labs for more than four decades, shares her take on the future of cancer medicine.
A future in which precision medicine benefits everyone is not guaranteed. For that to happen, UCSF experts argue, the health care industry must first tackle today’s health disparities, including differences in disease outcomes and access to care based on race, gender, and socioeconomic status.
No one can see the future, but that won’t stop us from trying. We asked UCSF faculty and alumni to score these predictions for likelihood and impact.
From international awards for high-caliber research to groundswell movements for social change, this past year was an eventful one for the UCSF community.
Browse the stories that most engaged our readers in 2019.
Children and young adults with pediatric cancer are less likely to be alive five and 10 years following diagnosis if their health insurance is public, compared to those with private insurance.
In a breakthrough with important implications for the future of immunotherapy for breast cancer, UCSF scientists have found that blocking the activity of a single enzyme can prevent a common type of breast cancer from spreading to distant organs.